Zusammenfassung
Die Therapie der erektilen Dysfunktion hat sich im Laufe der letzten Jahrzehnte grundlegend gewandelt. Die Phosphodiesterase-5-Inhibitoren (PDE-5-Inhibitoren) sind die First-line-Therapie. Zugelassen in Europa sind Sildenafil, Tadalafil, Vardenafil und Avanafil. Die Substanzen zeigen ähnliche Erfolgs- und Nebenwirkungspotentiale. Die absolute Kontraindikation ist die Einnahme von Nitraten. Durch diese therapeutische Vielfalt sollte es möglich sein, unter Zusammenarbeit aller ärztlichen Fachdisziplinen, unseren Patienten ein zufriedenstellendes Sexualleben zu ermöglichen bzw. wiederherzustellen.
Abstract
Due to the large number of drugs now available, the therapy of erectile dysfunction has changed profoundly in recent decades. The phosphodiesterase type 5 inhibitors (PDE5-i): sildenafil, taldalafil, vardenafil, and avanafil are EMA European Medicines Agency approved and show similar adverse events and success rates. The absolute contraindication is the simultaneous use of nitrates. Despite this wide variety of options, therapy of erectile dysfunction should be performed in an individually adapted manner. The exact patient’s history, physical examination, collaboration of medical disciplines, and choice of therapy will offer every patient the possibility to achieve or regain a satisfying sexual life.
Literatur
Stief CG, Truss MC, Becker AJ, Kuczyk M, Jonas U (2000) Pharmakologische Therapiemöglichkeiten der Erektionstörung. Dtsch Arztebl 97:457–460
Montorsi F, Deho F, Salonia A, Cestari A, Guazzoni G, Rigatti P, Stief CG (2003) Pharmacological management of erectile dysfunction. BJU Int 91:446–454
Porst H (1996) The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 155:802–815
Montorsi F, Salonia A, Zanoni M, Pompa P, Cestari A, Guazzoni G, Barbieri L, Rigatti P (2002) Current status of penile therapy. Int J Impot Res 14(Suppl.1):70–81
Leungwattanakij S, Flynn V, Hellstrom JG (2001) Intracavernosal injection and intraurethral therapy for erectile dysfunction. Urol Clin N Am 28:343–354
McMahon CG (2002) Topiglan macrochem. Curr Opin Investig Drugs 3:602–6006
McVary KT, Polepalle S, Riggi S, Pelham RW (1999) Topical prostaglandin E1 SEPA gel for the treatment of erectile dysfunction. J Urol 162:726–731
Guay AT, Perez JB, Jacobson J, Newton RA (2001) Efficacy and safety of sildenafil citrate for treatment of erectile dysfunction in a population with associated organic risk factors. J Androl 22:793–797
Sperling H, Michel MC, Rübben H (1999) Sildenafil (Viagra) Verträglichkeit, Kontraindikationen, Arzneimittelintraktionen. Urologe A 38:124–127
Mydlo JH, Volpe MA, Macchia RJ (2000) Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction. BJU Int 86:469–473
Arruda-Olson AM, Mahoney DW, Nehra A, Leckel M, Pellikka PA (2002) Cardivascular effects of sildenafil during exercise in men with known or probable coronary artery disease. JAMA 287:719–725
Fox K, Thadani U, Ma PTS, Nash SD, Keltai M (2001) Time to onset of limiting angina during treadmill exercise in men with erectile dysfunction and stable chronic angina: effect of sildenafil citrate. Circulation 104(Suppl.):2841
Mitka M (2000) Some men who take viagra die – why? JAMA 285:590–593
Shakir SAW, Wilton LV, Bshier A, Layton D, Heeley E (2001) Cardiovascular events in users of sildenafil: result from first phase of prescription event monitoring in England. BMJ 322:651–652
Spivack AP, Peterson CA, Cowley C, Hall M, Nemo KJ, Stephens D, Tam PY, Todd LK, Place VA (1997) Long-term safety profile of transurethral alprostadil for the treatment of erectile dysfunction. J Urol 157:A792
Porst H (2002) IC351 (tadalafil, cialis): update on clinical experience. Int J Impot Res 14(Suppl.1):57–64
Shabsigh R, Padma-Nathan H, Gittleman M (2000) Intracavernous alprostadil alfadex is more efficious, better tolerated and preferred over intraurethral alprostadil plus optional ACTIS: a comparative, randomised, crossover, multicenter study. Urology 55:109–113
Dell’Atti L (2015) Tadalafil once daily and intralesional verapamil injection: a new therapeutic direction in Peyronie’s disease. Urol Ann 2015:345–349
Pomeranz HD, Smith KH, Hart WM (2002) Sildenafil-associated nonarteritic anterior Ischemic optic neuropathy. Ophthalmology 109:584–587
Burnett AL, Anele UA, Truehart IN, Strouse JJ, Casella JF (2014) Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease. Am J Med 127:664–668
Sanford M (2013) Avanafil: a review of its use in patients with erectile dysfunction. Drugs Aging 30(10):853–862
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Interessenkonflikt
H. Sperling: Vortragshonorare bzw. Berater und Studientätigkeit bei Lilly, Pfizer und Jenapharm, Bayer.
Dieser Beitrag beinhaltet keine vom Autor durchgeführten Studien an Menschen oder Tieren.
Rights and permissions
About this article
Cite this article
Sperling, H. Nebenwirkungen der medikamentösen Behandlung der erektilen Dysfunktion. Urologe 56, 451–455 (2017). https://doi.org/10.1007/s00120-017-0341-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00120-017-0341-4